PRPeter H. Rheinstein

Peter H. Rheinstein

*This is an algorithmically generated author record based on publicly available information.

Peter H. Rheinstein has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Estradiol exposure and pancreatic cancer risk: convergent evidence from population-based incidence, pharmacovigilance, and tumor biology

    by Steven Lehrer, Peter H. Rheinstein

    Aim: To evaluate whether estrogen exposure is associated with pancreatic ductal adenocarcinoma (PDAC) risk and to determine whether estrogen signaling influences tumor biology, integrating population-based incidence, pharmacovigilance, and transcriptomic data. Methods: We conducted a multi-modal analysis using four complementary data sources. Population-based incidence was assessed using Surveillance, Epidemiology, and End Results (SEER) multiple-primary standardized incidence ratio (MP-SIR) methodology among female breast cancer survivors, with latency stratification. Pharmacovigilance disproportionality analysis of estradiol-associated pancreatic cancer reports was performed using OpenVigil access to the Food and Drug Administration Adverse Event Reporting System (FAERS), calculating proportional reporting ratios (PRRs), reporting odds ratios (RORs), and χ2 statistics. A prospective UK Biobank cohort analysis evaluated self-reported ever use of hormone replacement therapy (HRT) and incident registry-confirmed PDAC using a 5-year landmark and multivariable Cox proportional hazards regression. Tumor transcriptomic associations between estrogen receptor 1 (ESR1) signaling and stromal programs were examined in The Cancer Genome Atlas Pancreatic Adenocarcinoma (TCGA-PAAD) using Spearman correlation and nonparametric group comparisons. Results: In SEER, pancreatic cancer incidence among breast cancer survivors was comparable to the general population (SIR 1.03, 95% CI 1.00–1.07), with no elevation in early or late latency periods. In contrast, pharmacovigilance analysis demonstrated a strong inverse association between estradiol exposure and pancreatic cancer reporting (PRR and ROR 0.095; χ2 = 76.674). In the UK Biobank, 265,572 women contributed 705 incident PDAC events after the 5-year landmark. Ever use of HRT was not significantly associated with PDAC after adjustment for age, body mass index, smoking status, type 2 diabetes, and socioeconomic deprivation (HR 1.16, 95% CI 0.99–1.36; p = 0.059). TCGA analyses revealed a significant positive association between ESR1 expression and inflammatory, tumor-restraining cancer-associated fibroblast programs (p < 1 × 10–6). Conclusions: Estrogen exposure was not associated with a statistically significant reduction in PDAC incidence. Pharmacovigilance and transcriptomic findings support a possible tumor-modifying role for estrogen signaling, whereas the UK Biobank results do not demonstrate a protective association between broadly defined HRT use and PDAC incidence.

  • Open Access

    Multi-Layered Dysregulation of NRCAM in Lower-Grade Gliomas: Insights From TCGA Copy Number and Epigenetic Analyses

    by Steven Lehrer, Peter H. Rheinstein

    Neuronal cell adhesion molecule (NRCAM) has been implicated in glioma biology through splicing alterations reported by prior studies. However, the relative contributions of genomic and epigenetic mechanisms to NRCAM dysregulation in gliomas remain unclear. We analyzed data from The Cancer Genome Atlas (TCGA) Lower-Grade Glioma (LGG) cohort using UCSC Xena and cBioPortal. Copy number variation (CNV), DNA methylation (Illumina HumanMethylation450 BeadChip arrays), and mutation profiles were assessed for NRCAM. Kaplan-Meier survival analyses were performed with Xena, stratifying patients by copy number status and methylation state. Correlations between mutation burden and fraction of genome altered (FGA) were evaluated using Spearman and Pearson methods. Somatic mutations in NRCAM were rare in the TCGA-LGG cohort. In contrast, CNV and methylation changes were frequent and clinically relevant. Copy number gains at the NRCAM locus were associated with significantly shorter overall survival, while higher methylation of NRCAM correlated with improved survival outcomes. NRCAM mutation count did not show a linear correlation with FGA, suggesting these alterations are largely independent of overall genomic instability. The findings highlight copy number imbalance and epigenetic regulation as predominant mechanisms of NRCAM dysregulation. NRCAM is recurrently dysregulated in lower-grade gliomas through CNVs and DNA methylation, both of which stratify patient survival. Together with previously reported splicing deregulation, these data suggest that NRCAM functions as a multilayered regulator of glioma progression. NRCAM methylation may represent a potential prognostic biomarker, while therapeutic modulation of NRCAM warrants further investigation.


  • Open Access

    Eyeglasses Reduce Risk of COVID-19 Infection

    by Steven Lehrer, Peter Rheinstein

    Background/Aim: A study of patients in the Hubei Province, China, at the beginning of the pandemic demonstrated that among a group of 276 patients admitted to a hospital with laboratory-confirmed COVID-19, the proportion of patients who said they routinely wore eyeglasses more than 8 hours per day was lower than in the general population. Therefore, wearing eyeglasses more than 8 hours per day may be protective against SARS-CoV-2 infection, possibly because eyeglasses are a barrier that reduces the frequency with which people touch their eyes. The aim of the study was to determine if eyeglasses protect from COVID-19 infection. Materials and Methods: We used UK Biobank (UKB) data to corroborate findings of the Hubei study in the UK population. Results: Eyewear was associated with a reduced risk of infection, odds ratio (OR)=0.77. The effects of sex, age, and eyewear were independent and significant at the 95% level. Men are 1.24-times more likely to be infected than women; subjects’ risk of infection is less (0.95) for every year of age. Conclusion: The public at large may profit from wearing glasses, as well as wearing face masks and practicing social distancing.


  • Open Access

    Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening

    by Steven Lehrer, Peter H Rheinstein

    Steven Lehrer, MD, Peter H Rheinstein, MD, JD, MS; Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screen


  • Alzheimer Gene BIN1 may Simultaneously Influence Dementia Risk and Androgen Deprivation Therapy Dosage in Prostate Cancer

    by Steven Lehrer, Peter H. Md Rheinstein

    Background: Androgen deprivation therapy (ADT) is extensively used in prostate cancer. Yet the risk of impaired cognition or Alzheimer disease (AD) in men with prostate cancer receiving ADT is uncertain. Some studies of prostate cancer and ADT suggest that the risk of AD is not increased. But other studies have found an increased risk of AD and cognitive impairment. Objectives: As the uncertainty about ADT and dementia might relate to the genetics of prostate cancer and AD, the authors used the Cancer Genome Atlas (TCGA) to examine the relationship in men with prostate cancer between genes implicated in AD and genes implicated in prostate cancer. Methods: The authors examined the genomics of 492 prostate cancer cases in the Genomic Data Commons (GDC) TCGA Prostate Cancer (PRAD) data set. To access and analyze the data, 2 web-based interfaces were used: (1) the UCSC Xena browser, a web-based visual integration and exploration tool for TCGA data, including clinical and phenotypic annotations; and (2) cBioportal, a web-based interface that enables integrative analysis of complex cancer genomics and clinical profiles. Results: Co-occurrence analysis indicates that alterations in the prostate cancer gene Speckle-type POZ protein (SPOP) significantly co-occur with alterations in the AD gene BIN1 (PSPOP deranges BIN1 gene expression. SPOP/BIN1 RNA gene expression in 492 prostate cancer specimens is significantly correlated (PSPOP in 492 prostate cancers is associated with reduced survival (P=0.00275). Men receiving pharmacologic therapy had a tumor with a significantly higher Gleason score (P=0.023). Gleason score and BIN1 RNA gene expression, unit log2 (fragments per kilobase of transcript per million mapped reads upper quartile [FPKM-UQ]+1), in 499 prostate cancer specimens were significantly inversely correlated (PBIN1 forms part of a network that interacts with the MYC oncogene, activated at the earliest phases of prostate cancer and in its position on chr8q24 linked to disease aggressiveness. Dynamic regulation of the BIN1-Tau interaction is involved in AD. BIN1 loss in AD allows phosphorylated tau to be mis-sorted to synapses, which likely alters the integrity of the postsynapse, alongside reducing the functionally important release of physiological forms of tau. Alzheimer symptoms are usually preceded by a preclinical phase that may be 16 years long. The authors suggest that the ADT dosage reflects the severity of a process that is already underway. The severity is determined by the genetics of the tumor itself, at least in part by BIN1. ADT is not causing new cases of AD. The oncologist treats higher-grade prostate cancer with more ADT, which serves as a surrogate marker for disease severity. Our analysis of TCGA data does not support the idea that ADT causes AD or dementia.


  • Open Access

    Statins combined with niacin reduce the risk of peripheral neuropathy

    by Steven Lehrer, Peter H. Rheinstein

    Statins are a class of lipid-lowering medications that reduce illness and mortality in those who are at a high risk of developing cardiovascular disease. They are the most common cholesterol-lowering drugs. A case control study published in 2002 indicated that statins may increase the risk of peripheral neuropathy. Statin users were 14-fold more likely to develop peripheral neuropathy than non-users, although the overall risk of developing neuropathy was minimal. However, a number of other studies have produced conflicting results regarding neuropathy and statins. Statins are frequently combined with niacin (vitamin B3). Due to its beneficial effects on lipid profiles, niacin has been prescribed for the prevention of heart disease for >40 years. Among the B vitamins, niacin has long been recognized as a key mediator of neuronal development and survival, and may be of value for the treatment of neuropathy. The present study aimed to assess whether the combination of niacin and statin may reduce the risk of peripheral neuropathy attributed to statins. For this purpose, data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program were analyzed. The online tool OpenVigil 2.1 was used to query the databases. The results revealed that the majority of statins alone were related to neuropathy. Pitavastatin was the only exception. The association with neuropathy was most pronounced in the lipophilic statins: Atorvastatin and fluvastatin. The association was weaker for other lipophilic statins, such as lovastatin and simvastatin. Two hydrophilic statins, rosuvastatin and pravastatin, exhibited a similarly weaker association with neuropathy, while no reports of any association of pitavastatin with neuropathy were found. Statins + niacin were unrelated to neuropathy. On the whole, the findings of the present study demonstrate that the controversial association of statins with neuropathy may be due to the fact that previous studies have not included the use of niacin and the potential neuroprotective effects of niacin. Multiple reports have stated that niacin is no longer beneficial for the management of hyperlipidemia and should be abandoned. However, given the apparent ability of niacin to reduce the risk of neuropathy, perhaps niacin should not be discarded before further studies are performed to provide more in depth information.


  • Open Access

    Co-occurrent Alterations of Alzheimer's Genes and Prostate Cancer Genes in Prostate Cancer

    by Steven Lehrer, Peter H. Rheinstein

    Background: Androgen deprivation therapy (ADT) is extensively employed in treatment of prostate cancer. Some studies have found increased risk of Alzheimer's disease and cognitive impairment in patients treated with ADT. Aim: Since the uncertainty about ADT and dementia might relate to the genetics of prostate cancer and Alzheimer's disease, we used the Cancer Genome Atlas (TCGA) to examine the relationship between genes implicated in Alzheimer's disease and genes implicated in prostate cancer in men with prostate cancer. Materials and Methods: The genomics of 492 prostate cancer cases in the Genomic Data Commons TCGA Prostate Cancer data set were examined. Results: Alterations (mutation, amplification or deletion) in prostate cancer gene speckle-type POZ protein (SPOP) significantly co-occurred with alterations in Alzheimer's disease gene bridging integrator-1 (BIN1). Alterations in prostate cancer gene spectrin alpha 1 (SPTA1) significantly co-occurred with alterations in Alzheimer's disease gene CD2-associated protein (CD2AP) (p<0.001). The presence of somatic mutations (deleterious and missense/in frame) in SPOP disturbs BIN1 gene expression. SPOP and BIN1 RNA expression in 492 prostate cancer specimens was significantly positively correlated (p<0.001). Increased expression of SPOP in 492 cases of prostate cancer was associated with reduced survival (p=0.00275). BIN1 forms part of a network that interacts with the MYC oncogene, which is activated at the earliest phases of prostate cancer and is linked to disease aggressiveness. Men receiving ADT had tumor with a significantly higher Gleason score (p=0.023). Gleason score and BIN1 RNA expression in 499 prostate cancer specimens were significantly correlated (p<0.001). Conclusion: The severity of prostate cancer is determined by the genetics of the tumor itself, possibly at least in part by the interactions of SPOP/BIN1, MYC/BIN1 and SPTA1/CD2AP. Oncologists treats higher grade prostate cancer with more ADT, which serves as a surrogate marker for disease severity. A weakness of our study is that we did not examine Alzheimer's disease or dementia at all in patients with cancer, only co-occurrence of genetic alterations. Nevertheless, our analysis of TCGA data does not support the idea that ADT causes Alzheimer's disease or dementia.


  • Increased Risk of Acute Myelogenous Leukemia After Early Onset but Not Late-Onset Colorectal Cancer

    by Steven Lehrer, Peter H. Md Rheinstein

    Background: Early onset colorectal cancer in persons younger than 50 years is increasingly common. Clinical and molecular characterizations reveal a distinctive disease. Thirty percent of patients have mutations of hereditary cancer syndromes, especially Lynch syndrome. A recent analysis, testing germline DNA for mutations in 25 cancer susceptibility genes, showed that some patients younger than 50 years had mutations of high-penetrance colorectal cancer genes such as APC (adenopolyposis coli). Others had mutations in high-penetrance or moderate-penetrance genes not traditionally associated with colorectal cancer, such as ATM (ataxia telangiectasia mutated), whereas still others had low penetrance colorectal cancer genes. In the current study, we examined the incidence of second cancers following early onset (age less than 50 y) colorectal cancer. Methods: The initial study population was assembled using records from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute. The SEER*Stat MP-SIR (multiple primary-standardized incidence ratio) tool was used to calculate SIRs and excess risk for second primary malignancies. The SIR is expressed as the ratio of observed-to-expected (O/E) cases. We used The Cancer Genome Atlas (TCGA) and AACR Project Genie for genetic analysis. The data were accessed with the online Xena Browser and cBioportal. Results: Acute myelogenous leukemia (AML) O/E ratios were significantly >1 in patients aged less than 50 years, at 12 to 59 months after colorectal cancer. In patients aged 50 years and older, O/E ratios were equal to 1 or quite close at 12 to 59 months after colorectal cancer. Alterations in 3 AML genes, CEBPA-AS1, MLLT1, and MLLT6, affected the prognosis of colorectal cancer patients less than 50 years but not older than 50 years. One AML gene, FLT3, had the highest copy number alteration frequency of any gene in 1438 colorectal patients 18 to 48 years of age. Genetic alterations of FLT3/TP53 were mutually exclusive. Genetic alterations of FLT3/JAK2 and JAK2/CTNNB1 were co-occurrent. Conclusion: These observations suggest that early onset colorectal cancer and AML may be related diseases.


    • 1 October 2019
      • Vol. 28  (154) , 205-212

    Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Reduce Suicidal Ideation and Depression

    by Steven Lehrer, Peter H. Rheinstein

    Background. Neuroinflammation has been implicated in depression. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been found effective in treating animal models of depression, alone or with antidepressant drugs. However, results with NSAIDs have been mixed in human observational studies, with both better and worse depression outcomes reported. In the current study, we evaluated the effect of NSAIDs on suicidal ideation and depression. Methods: We used data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program. Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database. We used the online tool OpenVigil 2.1 to query the database. OpenVigil calculates proportional reporting ratios (PRRs) from adverse drug reaction reports to determine whether the combination of drug and adverse event are related. Results: Significantly less suicidal ideation was reported in patients treated with ibuprofen, naproxen, celecoxib, or aspirin (NSAIDs) compared to acetaminophen (a non-NSAID). Significantly less depression was reported in patients treated with naproxen or aspirin compared to acetaminophen, but significantly more depression in patients treated with celecoxib compared to acetaminophen. Ibuprofen in women but not men was associated with significantly less depression. Conclusion: Only 1-2% of an oral NSAID dose reaches the brain. We have proposed a new route of administration for drugs to treat neuropsychiatric illnesses: Trans-spinal delivery by transdermal patch over the back-of-neck/cervical spine. The drug would diffuse from the patch through the intervertebral spaces, penetrate the dura, and enter the CSF, where it would reach the brain. NSAIDs might be valuable agents for treating depression and suicide, as is supported by this study, especially if they can reach the brain at a higher concentration. Further studies of NSAIDs in these conditions are warranted.